European Biosimilars' Market Performance Mirrors US Legislative Progress: Slow but Steady
This article was originally published in RPM Report
Executive Summary
Biosimilars haven't had a huge impact in Europe-yet. Sponsors and analysts expect that to change over time. Will the US market parallel the European experience?